Vivos Therapeutics, Inc. (VVOS) - Dilution Analysis

10-Q filing | 14.6M shares outstanding

8-K filing: Vivos Therapeutics, Inc. sold shares and warrants to V-Co Investors 3 LLC in a private placement offering. ($1.72M proceeds)

8-K filing: Vivos Therapeutics, Inc. completed a warrant inducement agreement with a Holder, resulting in the exercise of existing warrants and the issuance of new warrants in a private placement transaction. ($4.6M proceeds)

POS AM filing: This prospectus relates to the resale of common stock issuable upon exercise of warrants by the selling stockholder.

10-Q filing | 9.0M shares outstanding

S-3/A filing: Vivos Therapeutics, Inc. may offer and sell common stock, preferred stock, warrants, subscription rights, debt securities, or units for total gross proceeds of up to $50,000,000.

10-Q filing | 7.5M shares outstanding

8-K filing: Vivos Therapeutics, Inc. completed the acquisition of The Sleep Center of Nevada, entered into a senior secured loan with Streeterville Capital, LLC for $8,250,000, and completed a private placement offering with V-Co Investors 2 LLC for gross proceeds of $3,655,000. ($7.97M proceeds)

10-Q filing | 5.9M shares outstanding

10-K filing | 5.9M shares outstanding

S-3 filing: Vivos Therapeutics, Inc. is filing an S-3 to offer common stock, preferred stock, warrants, subscription rights and debt securities for total gross proceeds of up to $50,000,000.

S-1/A filing: This S-1/A filing, dated January 29, 2025, relates to the offer for sale of up to 854,332 shares of Common Stock by selling stockholders, including shares underlying warrants issued in December 2024 and September 2024 private placements.

S-1 filing: This is an offering of up to 854,332 shares of Common Stock, including shares issuable upon exercise of warrants.

8-K filing: Vivos Therapeutics Inc. entered into a securities purchase agreement for a registered direct offering to sell 709,220 shares of common stock and warrants to purchase up to 709,220 shares of common stock at a combined purchase price of $4.935 per share and warrant. ($3.5M proceeds)

10-Q filing | 4.8M shares outstanding

8-K filing: Vivos Therapeutics Inc. entered into a securities purchase agreement for a registered direct offering to purchase 1,363,812 shares of common stock at $3.15 per share, with gross proceeds expected to be approximately $4.3 million before deducting fees and expenses. ($4.3M proceeds)

10-Q filing | 3.2M shares outstanding

S-3 filing: The filing relates to the registration of offer and sale of Selling Stockholder Shares pursuant to certain registration rights granted to the selling stockholder.

8-K filing: Vivos Therapeutics, Inc. completed a private placement offering of 169,498 shares of common stock, a pre-funded warrant to purchase 3,050,768 shares of common stock, and a common stock purchase warrant to purchase up to 3,220,266 shares of common stock to V-CO Investors LLC for gross proceeds of $7,500,000. ($7.5M proceeds)

10-Q filing | 3.2M shares outstanding

S-1/A filing: This S-1/A filing registers shares underlying warrants from previous private placements for public resale and discusses business updates, including the Treatment Navigator program and private placements in January and November 2023.

S-1 filing: This is an S-1 filing registering shares underlying warrants from previous private placements.

10-K filing | 2.7M shares outstanding

8-K filing: Vivos Therapeutics, Inc. closed the exercise of Series B Warrants for $4.0 million, resulting in the issuance of 980,393 shares of common stock at $4.02 per share, and agreed to issue new warrants to purchase 1,470,592 shares of common stock as inducement. ($4.0M proceeds)

S-1/A filing: This prospectus relates to the offer for sale of up to an aggregate of 2,941,179 shares of common stock of Vivos Therapeutics, Inc., by the selling stockholder.

S-1 filing: This S-1 filing relates to the offer for sale of up to 2,941,179 shares of common stock of Vivos Therapeutics, Inc., by the stockholder named herein.

10-Q filing | 1.2M shares outstanding

8-K filing: Vivos Therapeutics, Inc. closed a private placement on November 2, 2023, selling 980,393 shares of common stock (or pre-funded warrants in lieu thereof) at $4.08 per share, along with warrants to purchase additional shares, resulting in net proceeds of approximately $3.5 million for general working capital and corporate purposes. ($4.0M proceeds)

8-K filing: Stock split 1-for-25 | Outstanding: 29,928,786 → 1,197,151

10-Q filing | 29.9M shares outstanding

10-Q filing | 29.9M shares outstanding

10-K filing | 29.7M shares outstanding

8-K filing: Vivos Therapeutics, Inc. acquired certain assets from Advanced Facialdontics, LLC, including patents and trademarks, in exchange for cash, common stock, earnout payments, royalties, milestone payments, and a warrant to purchase common stock.

S-1 filing: This S-1 filing relates to the offer for sale of up to an aggregate of 13,333,334 shares of common stock of Vivos Therapeutics, Inc., by the selling stockholder.

8-K filing: Vivos Therapeutics, Inc. entered into a Securities Purchase Agreement to sell up to $8,000,000 of securities in a private placement, consisting of 2,000,000 shares of common stock and pre-funded warrants to purchase up to 4,666,667 shares of common stock and common stock purchase warrants to purchase up to 6,666,667 shares of common stock, with the private placement expected to close on January 9, 2023. ($8.0M proceeds)

10-Q filing | 23.0M shares outstanding

10-Q filing | 23.0M shares outstanding

10-Q filing | 21.2M shares outstanding

10-K filing | 23.0M shares outstanding

S-3 filing: Vivos Therapeutics, Inc. may offer and sell common stock, preferred stock, subscription rights, and debt securities for total gross proceeds of up to $75,000,000.

10-Q filing | 23.0M shares outstanding

10-Q filing | 22.8M shares outstanding

S-1/A filing: This S-1/A filing relates to the offer for sale of up to 9,710,010 shares of common stock by certain stockholders and the issuance of up to 402,500 shares of common stock underlying a warrant issued to Roth Capital Partners, LLC.

10-Q filing | 22.8M shares outstanding

8-K filing: Vivos Therapeutics, Inc. consummated a follow-on, underwritten public offering of 4,600,000 shares of common stock at a price of $6.00 per share, generating gross proceeds of $27,600,000. ($27.6M proceeds)

S-1 filing: This is an S-1 filing for BioModeling Solutions, Inc. describing their initial public offering on December 11, 2020, where 4,025,000 common shares were offered at $6.00 per share.

S-1 filing: This S-1 filing relates to the offer for sale of up to 9,710,010 shares of common stock by selling stockholders and the issuance of up to 402,500 shares of common stock underlying a warrant issued to Roth Capital Partners, LLC.

8-K filing: Vivos Therapeutics, Inc. announced the launch of a new service called MyoCorrect and issued warrants to purchase 200,000 shares of the Company's common stock to an OMT therapist, with an exercise price of $7.50 per share, some of which vested immediately.

10-K filing | 18.2M shares outstanding

8-K filing: Vivos Therapeutics, Inc. consummated its initial public offering of 4,025,000 shares of common stock at a price of $6.00 per share, generating gross proceeds of $24,150,000. ($24.15M proceeds)

S-1/A filing: This S-1/A filing describes a proposed offering of 3,333,334 shares of common stock at an assumed price of $6.00 per share, and discusses potential dilution from outstanding options, warrants, and preferred stock, as well as risks related to Nasdaq listing requirements.

S-1/A filing: This S-1/A filing describes a proposed offering of 3,333,334 shares of common stock at an assumed price of $6.00 per share, and discusses potential dilution from the exercise of options, warrants, and convertible securities.

S-1/A filing: This S-1/A filing discusses the potential dilution to stockholders from the offering of 3,333,334 shares of common stock, the exercise of outstanding options and warrants, and the possible issuance of equity for acquisitions or alliances. It also mentions the risk of delisting from the Nasdaq Capital Market if continuing listing requirements are not met.

S-1 filing: This is an S-1 filing for the initial public offering of 3,333,334 shares of common stock of Vivos Therapeutics, Inc.